Medicine shortages: impact behind numbers

Abstract

Introduction Current research to assess the impact that medicine shortages have on patients is limited to general aspects, such as the prevalence of shortages and product characteristics. The aim of this study is to assess the overall impact that medicine shortages have on economic, clinical, and humanistic outcomes. Methods A cohort of all known products in shortage in the Netherlands between 2012 and 2015 were characterized by their route of administration, anatomical therapeutic chemical class, and whether they were originator or generic products. A representative sample of 324 shortages (18% of all shortages) was rated as having low, medium, or high impact on the five elements that determine the impact of shortages on patients: availability of an alternative product, underlying disease, susceptibility of the patient, costs (for patients and society at large), and number of patients affected. Ratings were converted into numerical scores per element and multiplied to obtain an overall impact score. Results Two elements were most frequently rated as having a high impact: disease (29%) and costs (20%). Nearly half of the shortages (47%) rated high on at least one element, while nearly 10% rated high on multiple elements. Thirty percent of the shortages rated high on direct impact, which is represented by these elements: alternative product and disease. An additional 17% of the shortages rated high on indirect impact, which is represented by these elements: costs, susceptibility, and number of patients. High impact scores could not significantly be attributed to characteristics of the products in shortage. Conclusions An assessment of the medicine shortages’ impact using a framework based on economic, clinical, and economic outcomes showed that all three outcomes affect the overall impact that medicine shortages have on patients.

The association between drug pricing and drug shortage in Saudi Arabia: a retrospective database analysis

“…It has emerged as a significant global challenge due to its multifaceted nature and the adverse clinical, social, and economic consequences it entails [ 1 – 21 ]. A recent study found that a large percentage of drug shortage incidents in the Netherlands were anticipated to have moderate to high negative clinical, humanistic or economic patient impacts [ 22 ]. Various studies have identified clinical, economic, regulatory, and policy-related factors as contributors to drug shortages [ 1 – 21 ].…”

Price increase negotiations to address drug shortages in South Korea’s national health insurance

“…When supply falls short of demand, resulting in a drug shortage, patients may experience exacerbated conditions and be exposed to side effects due to inappropriate substitute medications ( Tucker et al, 2020 ). Furthermore, societal costs arise from the additional time and effort expended by healthcare providers searching for alternative drugs or treatments, elevating drug shortage from a purely medical problem to a broader societal concern ( Pauwels et al, 2014 ; Postma et al, 2023 ).…”

Post COVID availability of oncology drugs – Is this the new normal on both sides of the Atlantic?

“…4,5 Although global mitigation strategies have been developed to overcome these shortages, patients, pharmacists, clinicians and other healthcare professionals are still affected worldwide. 2,6,7 Drug shortages have been further exacerbated by the long-lasting effects of the COVID-19 pandemic. The pandemic has caused significant supply chain issues for pharmaceutical manufacturers those in the generic drug market.…”

“…4,5 Although global mitigation strategies have been developed to overcome these shortages, patients, pharmacists, clinicians and other healthcare professionals are still affected worldwide. 2,6,7…”